Delcath Systems, Inc. (DCTH) Starts Presentation at LD Micro Main Event
Delcath Systems, Inc. (OTC: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Delcath’s investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Melphalan/HDS has not yet been approved by the FDA for sale in the U.S. The system has been commercially available in Europe since 2012, where it has been used at major medical centers to treat a wide range of cancers of the liver. For more…







